New Biomarker, Subgroup Analyses of Phase 3 NefIgArd Trial f

Positive findings from NefIgArd demonstrated budesonide’s ability to modulate the intestinal immune network responsible for IgA production.

Related Keywords

Tokyo , Japan , Jonathan Barratt , Richard Phillipson , International Symposium On Iga Nephropathy Iigann Tokyo , Drug Administration , International Symposium On Ig , International Symposium On Iga Nephropathy , George Clinical , Calliditas Therapeutics , Cc Motif Chemokine Ligand , International Symposium , Chief Medical Officer , Prescription Drug User Fee Act , Iga Nephropathy , Mayer Professor , Renal Medicine , Calliditas Presents Data , Nefigard Phase , Calliditas Therapeutics Accelerated Approval , Reduce Proteinuria , Patients With Primary Iga , Igard Trial Evaluating Nefecon , Immunoglobulina Nephropathy , Wigan , Nefigard , Budesonide , Nefecon , Tarpeyo ,